BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - BioArctic AB's (BIOA-B.ST) partner Eisai (4523.T) announced that they have filed a new drug application for Leqembi or lecanemab for a subcutaneous formulation as a new route of administration to Japan's Pharmaceuticals and Medical Devices Agency. The application is based on data from multiple subcutaneous administration sub-studies of lecanemab conducted as part of the Phase 3 Clarity AD open-label extension, following the 18-month core study in individuals with Mild Cognitive Impairment due to Alzheimer's disease or mild stage of AD dementia.
Leqembi is the result of a collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic.
For More Such Health News, visit rttnews.com.
Copyright(c) 2025 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2025 AFX News
